Research of gene transfer into nonhuman promates using novel types of adenovirus vectors

使用新型腺病毒载体将基因转移到非人类原始动物中的研究

基本信息

项目摘要

Adenovirus(Ad) serotype 35(Ad35) vectors are promising gene delivery vehicles. However, the transduction profiles of Ad35 vectors in conventional mice allow a limited estimation of transduction properties of Ad35 vectors due to the restricted expression of the mouse analog of the subgroup B Ad receptor, CD46, in the testis. To properly assess the transduction properties of Ad35 vectors, we performed transduction experiments using cynomolgus monkeys, which ubiquitously express CD46 in a pattern similar to that in humans. In vitro transduction experiments demonstrated that cultured cynomolgus monkey cells were efficiently transduced with Ad35 vectors. By contrast, Ad35 vector-mediated transduction was hardly found in the all organs, although Ad35 vector genomes were detected in vanous organs following intravenous administration. Less severe histopathological abnormalities were found in the Ad35 vector-infused monkeys compared with the conventional Ad serotype 5(Ad5) vector-injected monke … More ys, in which serious tissue damages and inflammatory responses, such as hepatocyte necrosis and lymphatic hyperplasia in the colon, were induced. Both Ad35 and Ad5 vectors caused similar hematological changes(increase in CD3^+ cells, and decreases in CD16^+ cells and CD20^+ cells) in peripheral blood cells postinjection.Furthermore, Ad35 vectors were locally injected into the organs. Ad35 vectors exhibited unique transduction patterns depending on the organs. Hepatocytes and microglia were mainly transduced with Ad35 vectors after injection into the liver and brain, respectively. Intramuscular injection of Ad35 vectors resulted in transduction of cells which appealed to be fibroblasts and macrophages. Conjunctival epithelial cells express transgene expression following infusion into the vitreous body of eyeball. In these organs, transgene expression was limited to areas around the injection points. Transgene expression was not found in the organs which did not receive Ad35 vector injection. These results suggest that Ad35 vectors would be a preferable gene delivery vehicle by direct administration in the organs. Less
腺病毒(Ad)血清35型(Ad35)载体是一种很有前途的基因载体。然而,由于B亚组Ad受体的小鼠类似物CD46在睾丸中的有限表达,传统小鼠中Ad35载体的转导谱允许对Ad35载体的转导特性进行有限的估计。为了正确评估Ad35载体的转导特性,我们用食蟹猴进行了转导实验,食蟹猴以类似于人类的模式普遍表达CD46。体外转导实验表明,Ad35载体能有效地转导食蟹猴细胞。静脉注射Ad35载体后,各脏器中均可检测到Ad35载体的基因组,而Ad35载体介导的转导在所有器官中几乎未见。与传统的Ad5(Ad5)载体注射猴…相比,注射Ad35载体的猴的组织病理学异常较轻诱发严重的组织损伤和炎症反应,如肝细胞坏死和结肠淋巴组织增生。Ad35和Ad5载体注射后外周血细胞出现相似的血液学改变(CD3^+细胞增多,CD16^+细胞和CD20^+细胞减少)。Ad35载体在不同器官中表现出独特的转导模式。肝细胞和小胶质细胞分别注射入肝和脑后,主要由Ad35载体转导。肌肉注射Ad35载体可诱导细胞转导为成纤维细胞和巨噬细胞。结膜上皮细胞在注入眼球玻璃体后表达转基因。在这些器官中,转基因表达仅限于注射点周围区域。未接受Ad35载体注射的器官中未见转基因表达。这些结果表明,Ad35载体可能是一种通过器官直接给药的较好的基因输送载体。较少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
新しいアデノウイルスベクターの開発
新型腺病毒载体的开发
Evaluation of adenovirus serotype 35 vector-mediated gene transfer in cynomolgus monkeys.
腺病毒血清型 35 载体介导的食蟹猴基因转移的评估。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fuminori Sakurai;Kimiyo Akatomo;Kenji Kawabata;Shin-ichiro Nakamura;Hiroaki Shibata;Kenji Terao;Takao Hayakawa;Hiroyuki Mizuguchi
  • 通讯作者:
    Hiroyuki Mizuguchi
Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates
  • DOI:
    10.1038/mt.2008.19
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
    12.4
  • 作者:
    Sakurai, Fuminori;Nakamura, Shin-ichiro;Mizuguchi, Hiroyuki
  • 通讯作者:
    Mizuguchi, Hiroyuki
カニクイザルにおける35型アデノウイルスベクターの遺伝子導入特性
35型腺病毒载体在食蟹猴体内的基因转移特性
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    櫻井文教;他
  • 通讯作者:
Transduction properties of adenovirus serotype 35 vectors in cynomolgus monkeys.
腺病毒血清型 35 载体在食蟹猴中的转导特性。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fuminori Sakurai;Kimiyo Akitomo;Kenji Kawabata;Shin-ichiro Nakamura;Hiroaki Shibata;Keiji Terao;Takao Hayakawa;Hiroyuki Mizuguchi
  • 通讯作者:
    Hiroyuki Mizuguchi
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIZUGUCHI Hiroyuki其他文献

MIZUGUCHI Hiroyuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIZUGUCHI Hiroyuki', 18)}}的其他基金

Regulation of mammalian neuronal system by a novel microRNA "mirtron".
通过新型 microRNA“mirtron”调节哺乳动物神经系统。
  • 批准号:
    24659033
  • 财政年份:
    2012
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
The development of the novel targeted adenovirus vectors
新型靶向腺病毒载体的研制
  • 批准号:
    22390030
  • 财政年份:
    2010
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Exploring natural resources-derived compounds that suppress up-regulation of histamine H1 receptor gene expression as a diseases-sensitive gene
探索源自自然资源的化合物,抑制组胺 H1 受体基因表达上调作为疾病敏感基因
  • 批准号:
    22580132
  • 财政年份:
    2010
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Self-Compacting concrete Using Whole Recycled Materials from Demolished Concrete Structure as Aggregate and Powder by High grade Recycling System
高品位回收系统以拆除混凝土结构的全部回收材料为骨料和粉末开发自密实混凝土
  • 批准号:
    17560408
  • 财政年份:
    2005
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Water Purification Systems using Porous Concrete with Little Maintenance
使用多孔混凝土开发几乎不需要维护的水净化系统
  • 批准号:
    12450179
  • 财政年份:
    2000
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

ICF: A novel dual-target gene therapy for safe and efficacious treatment of chronic non-infectious uveitis
ICF:一种安全有效治疗慢性非感染性葡萄膜炎的新型双靶点基因疗法
  • 批准号:
    MR/Z50385X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Research Grant
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
  • 批准号:
    10087446
  • 财政年份:
    2024
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Collaborative R&D
Longitudinal structural and cognitive functional imaging and outcome prediction in focal epilepsy treated with gene therapy and surgical resection.
基因治疗和手术切除治疗局灶性癫痫的纵向结构和认知功能成像及结果预测。
  • 批准号:
    MR/X031039/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Research Grant
GeneT: The Gene Therapy CoE at the Center of Portugal
GeneT:葡萄牙中心的基因治疗 CoE
  • 批准号:
    10090933
  • 财政年份:
    2024
  • 资助金额:
    $ 10.23万
  • 项目类别:
    EU-Funded
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Research Grant
SBIR Phase I: Development of an Adjustable Gene Therapy Platform Technology
SBIR 第一阶段:可调节基因治疗平台技术的开发
  • 批准号:
    2240683
  • 财政年份:
    2023
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Standard Grant
Exploration novel effects of SHED-TK-derived exosomes on TK/GCV suicide gene therapy
探索SHED-TK衍生的外泌体对TK/GCV自杀基因治疗的新作用
  • 批准号:
    23K15643
  • 财政年份:
    2023
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Gene expression profiling of skin ulcers for short-acting in vivo gene therapy
皮肤溃疡的基因表达谱用于短效体内基因治疗
  • 批准号:
    23K19673
  • 财政年份:
    2023
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Activation of long non-coding RNA by a gene therapy CRISPR/Cas9 approach to prevent vein graft failure
通过基因治疗 CRISPR/Cas9 方法激活长非编码 RNA 以预防静脉移植失败
  • 批准号:
    EP/X024563/1
  • 财政年份:
    2023
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Research Grant
Developing a gene therapy product to treat pressure ulcers in lower-limb amputees
开发一种基因治疗产品来治疗下肢截肢者的压力性溃疡
  • 批准号:
    2888189
  • 财政年份:
    2023
  • 资助金额:
    $ 10.23万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了